Treating chronic hepatitis D infections with new strategy

A novel combination therapy may be effective at treating patients with chronic hepatitis D infections.

In a study published in The New England Journal of Medicine, researchers randomly assigned 174 patients with chronic hepatitis D infections to one of four treatment groups: 2 milligrams of bulevirtide plus pegylated interferon alfa-2a, 10 milligrams of bulevirtide plus pegylated interferon alfa-2a, pegylated interferon alfa-2a alone or bulevirtide alone.

Compared with the other patient groups, a higher proportion of the patients in the 10-milligram combination therapy group achieved undetectable hepatitis D virus levels and normalization of alanine aminotransferase levels.

However, more patients in the combination therapy groups experienced adverse events such as leukopenia, neutropenia and thrombocytopenia.

The researchers concluded that 10 milligrams of bulevirtide plus pegylated interferon alfa-2a may offer patients with chronic hepatitis D infections a finite treatment regimen.

Read more: The New England Journal of Medicine

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.